Evidence map›Paper›PMID 39120923›Full record

ArticleCancer control : journal of the Moffitt Cancer Center

A Retrospective Analysis of the Efficacy of Oral Dexamethasone in Combination With Docetaxel Plus Ramucirumab Therapy for Previously Treated Lung Cancer.

Kosuke Hamai, Ryo Katsura, Shinya Miyake, Suguru Fujita, Shinpei Tada, Tetsu Hirakawa, Sayaka Ueno, Takuya Tanimoto, Nobuhisa Ishikawa

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer control : journal of the Moffitt Cancer Center. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Kosuke HamaiDepartment of Respiratory Medicine, Hiroshima Prefectural Hospital, Hiroshima, Japan.ORCID 0000-0002-8654-5532
Ryo KatsuraDepartment of Respiratory Medicine, Hiroshima Prefectural Hospital, Hiroshima, Japan.
Shinya MiyakeDepartment of Respiratory Medicine, Hiroshima Prefectural Hospital, Hiroshima, Japan.
Suguru FujitaDepartment of Respiratory Medicine, Hiroshima Prefectural Hospital, Hiroshima, Japan.
Shinpei TadaDepartment of Respiratory Medicine, Hiroshima Prefectural Hospital, Hiroshima, Japan.
Tetsu HirakawaDepartment of Respiratory Medicine, Hiroshima Prefectural Hospital, Hiroshima, Japan.
Sayaka UenoDepartment of Respiratory Medicine, Hiroshima Prefectural Hospital, Hiroshima, Japan.
Takuya TanimotoDepartment of Respiratory Medicine, Hiroshima Prefectural Hospital, Hiroshima, Japan.
Nobuhisa IshikawaDepartment of Respiratory Medicine, Hiroshima Prefectural Hospital, Hiroshima, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionDocetaxel plus ramucirumab (DTX + RAM) therapy is a standard treatment for previously treated lung cancer, but many adverse events have been reported. This retrospective study was conducted to examine if the side effects of DTX + RAM therapy can be minimized by the combined use of oral dexamethasone (DEX), and to assess the therapeutic effect of DTX + RAM in patients with recurrent lung cancer.

methodsForty patients with relapsed non-small cell lung cancer who underwent DTX + RAM therapy were divided into two groups based on the concomitant use of oral DEX, and the therapeutic effects and toxicities in the two groups were compared.

resultsThe objective response rate (ORR) was significantly better in the DEX group (

Indexed as

Antibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsCarcinoma, Non-Small-Cell LungDexamethasoneDocetaxelLung NeoplasmsRamucirumabAdministration, OralAdultAgedFemaleHumansMaleMiddle AgedNeoplasm Recurrence, LocalRetrospective StudiesAntibodies, Monoclonal, HumanizedDexamethasoneDocetaxelRamucirumabdexamethasonedocetaxelfluid retentionlung canceroverall survivalramucirumab

Identifiers

PMID39120923
PMCPMC11316262

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.